Asthma is a chronic lung disease that today affects more than 235 million people worldwide, and approximately 25 million in the United States (NHLBI). The disease is caused by inflammation of the airways, characterized by wheezing, chest tightness, coughing and shortness of breath due to narrowing and/or obstruction of the airways. There is currently no specific reason for the onset of asthma. However, studies show that asthma exists in society due to many genetic and environmental factors. Environmental factors include certain allergens and irritants such as mold, pet dander, weather, tobacco smoke, dust mites, strong inorganic odors, pollen, certain insects, and industrial dust. (NHLBI) Asthma is also caused by genetics, as some people are born with a hereditary tendency to have the disease, especially if their biological parents had the disease. Say no to plagiarism. Get a tailor-made essay on “Why violent video games should not be banned”? Get the original essay Asthma can occur anywhere in the world and is not limited geographically because of the aforementioned environmental risk factors can be found everywhere, but certain ethnic and racial groups are at higher risk for asthma, such as African Americans and Puerto Ricans, who are three times more likely to be hospitalized with the disease. (Holgate, 2010) Additionally, children who have had respiratory infections as children are a high risk group for asthma, as this can lead to weaker and more sensitive airways. If an infant or young child is exposed to viral infections or certain airborne allergens during the development of their respiratory system, the risk of contracting the disease is also higher. Although there is no exact origin of asthma, respiratory complications similar to asthma have been recorded in China since 2400 BC. Occupational asthma, which is a type of asthma that develops due to industrial dust and chemical irritants in the workplace, is a lung disorder that many workers are at risk of having. (NHLBI) This may continue to pose a risk to the community if regulations for improved and safe ventilation and air quality are not ensured or enforced to protect workers from irritants and allergens that could lead to the 'asthma. Another risk is that the quality of life of asthma patients will continue to decline if allergens and irritants continue to be exposed and produced. Asthma can lead to reduced quality of life due to asthma attacks, which can be fatal. It can affect a student's school life, leading to missed learning at school, or it can affect a worker by reducing their available time and energy devoted to work due to hospitalizations or emergency room visits. (NIAID, 2018) How to Solve the Problem Although the number of asthma patients who die from asthma each year is not very significant, many of these deaths can be prevented with proper care and treatment of the disease. (AsthmaMD) Although there is no cure for the disease, one strategy to reduce the pervasiveness of asthma is for asthma patients to follow the Asthma Action Plan, developed by the Institute national heart, lungs and blood. The action plan is a tabular guide for people with asthma to take their asthma medications correctly.medications, avoid triggers except exercise, respond to symptoms that appear to be worsening, monitor their level of asthma control, and provide instructions for seeking emergency care. if necessary. The action plan is divided into three wellness categories for asthma patients to identify their specific needs given their current condition. There are two main types of medications for asthma patients. The first type is long-term controller medications. This type of medication is generally used more for preventative measures and symptom control than for immediate symptom relief. Long-term controller medications help prevent asthma symptoms and can reduce airway inflammation; therefore, a common long-term controller treatment is inhaled anti-inflammatory corticosteroids, the dose depending on the a person's symptoms. (NHLBI) The second type of medications for asthma patients are quick-relief medications. Also called rescue medications, this type of medication is used for short-term relief of the symptoms of an asthma attack, helping the airways to open temporarily. A common quick-relief medication is a beta-2 agonist inhaler. (NHLBI)Another strategy used to acquire a solution to asthma is targeted research through clinical trials, funded by the National Institute of Allergy and Infectious Diseases. This research is done with the goal of understanding the specific immune responses that can lead to asthma and discovering how environmental exposures interact with an individual's genetics that cause a certain response resulting in asthma. (NIAID) An understanding of the answers can support and promote the development of asthma treatments and prevention strategies to improve the quality of life of asthma patients. The research program identified the main reactions to asthma, including rapid heartbeat, drowsiness, chest tightness and shortness of breath, coughing, wheezing, etc. Yang Yong Qing, a professor in Shanghai, China, has conducted extensive research on asthma medications, where the rate of asthma is very high due to increasing urban smog. After the professor and his research team tested thousands of drugs, they came up with the development of a drug called TSG12. Compared to the traditional and preferred short-term beta-2 agonist, TSG12 activates a protein that reduces airway resistance and causes the smooth muscle cells in the throat to relax, which causes the asthma problem. . (Yin, 2018) Additionally, repeated use of beta 2-agonist can lead to desensitization and decreased effectiveness, but studies of the drug TSG12 showed that desensitization was not induced. (Yin, 2018) The drug is expected to enter the market soon, but more clinical trials need to be conducted before the public can use TSG12. A cohort study conducted in Amsterdam, the Netherlands, showed effective high-altitude treatment that took place at an asthma center located at 1,600 meters above sea level and provides personalized, multifaceted treatment for patients suffering from Severe asthma in a low-trigger environment. (Hashimoto, 2018) Treatment results showed an increase in the quality of life and lung function of asthma patients. High-altitude climate therapy resulted in a significant decrease in blood eosinophil levels, suggesting an anti-inflammatory effect that may result from.